Retacrit

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2016
02420082016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Comprehensive physicochemical characterization and biological assays are essential parts in assessing quality attributes of… (More)
Is this relevant?
Review
2016
Review
2016
The World Health Organization defines a biosimilar as "a biotherapeutic product which is similar in terms of quality, safety and… (More)
  • table 1
  • table 2
  • figure 1
Is this relevant?
2016
2016
INTRODUCTION Chemotherapy-induced anemia (CIA) is a frequent complication among cancer patients, with elderly patients more… (More)
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Review
2016
Review
2016
INTRODUCTION There is an essential need for clinicians to understand the development and approval process of biosimilars… (More)
  • table 3
  • table 4
Is this relevant?
Review
2012
Review
2012
INTRODUCTION A "biosimilar" or "similar biological medicinal product" is a biological agent that is similar in terms of quality… (More)
  • table 1
  • table 2
Is this relevant?
2010
2010
To compare the quality of therapeutic erythropoietin (EPO) products, including two biosimilars, with respect to content… (More)
  • table I
  • table II
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Review
2009
Review
2009
This first phase of the first generation of modern biotechnology-derived protein drugs is now coming to an end with the… (More)
Is this relevant?
2008
2008
This year will see the first serious engagements in the biogenerics war, as two copycat versions of the world’s biggest-selling… (More)
  • table 1
Is this relevant?
2008
2008
Two patients with thalassemia minor and end-stage renal failure on hemodialysis were treated with epoetin zeta (Silapo, Retacrit… (More)
  • table 1
Is this relevant?